Investor Relations

Company Overview

We aspire to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer.

We are advancing programs in women’s health, including endometriosis-associated pain and egg maturation in assisted reproduction, including in vitro fertilization (IVF), and the prevention of pregnancy.

Over time, we intend to expand our development pipeline to include potential treatments for women's health.

FDA Approved Drugs: ORGOVYX (relugolix 120 mg), MYFEMBREE (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg)

Copyright West LLC. Share price minimum 15 minutes delayed. Market cap from previous market close.

Press Releases
July 28, 2021
Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates
July 20, 2021
Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids
July 14, 2021
Myovant Sciences to Host First Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on July 28, 2021
Events

SEC Filings

Filing date Description Form View

Annual report which provides a comprehensive overview of the company for the past year

10-K View HTML EX-101.INS - XBRL INSTANCE DOCUMENT

Annual report which provides a comprehensive overview of the company for the past year

10-K View HTML EX-101.INS - XBRL INSTANCE DOCUMENT